Article Sidebar

Submitted
Apr 20, 2021
Published
Apr 20, 2021
Download
PDF
Statistic
Read Counter : 122 Download : 37

Main Article Content

Abstract

The field of education has a long history of using the case study. The use of case studies has become of increasing interest to those in many areas of education and educational research .Now a days the use of case studies is becoming an interesting teaching tool.  The process of using case studies will aid student’s abilities to generate multiple pathways for certain circumstances and in understanding that there may be multiple, acceptable decisions for particular situations. The use of case study may range from extended case projects, thesis and dissertations with in depth research on hospitals, disease types. Case studies can be effectively used as a learning tool. The use of case studies in Pharm D curriculum can aid students improve their problem solving abilities and also practical problem solving skills. It also gives students confidence on real time work. Case studies improvise cost effective drug therapy and minimizes the incidence of drug interactions and adverse drug reactions. It is also an effective method on how students can improvise on oneself and have a check on one’s own improvement. Case study also helps students to become professionally sound and gain confidence in their field because they become versatile as each day passes by and also experienced in various aspects of drug therapy. Case studies are practical based which effectively can be used to understand new phenomenon. It also aids in bringing about new innovations in patient care by exploring the students in to real time practice.

Keywords

Case study individualizing regimen effective learning Cost minimization

Article Details

How to Cite
R.Srisha, & V.Shivashankar. (2021). Case study a key tool in Pharm D education. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(2), 175-178. https://doi.org/10.61096/ijrpp.v4.iss2.2015.175-178
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Jordan WM. Pulmonary embolism. Lancet 1961;1146-7.
  2. [2] Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM,Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
  3. [3] Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992;21:48-52.
  4. [4] WHO. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
  5. [5] Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
  6. [6] Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005;3:2471-8.
  7. [7] Baglin TP, Cousins D, Keeling DM, et al. Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. British Journal of Haematology 2006;136:26–9.
  8. [8] Hanley JP. Warfarin reversal. Journal of Clinical Pathology 2004;57:1132–9.
  9. [9] British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. British Journal of Haematology 1998;101:374–87.
  10. [10] Watson HG, Baglin T, Laidlaw, SL. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. British Journal of Haematology 2001;115:145–9.
  11. [11] Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrates on correction of the coagulopathy. Thrombosis and haemostasis. 1997;77:477–80.
  12. [12] Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clinical and Laboratory Haematology 2003;20:363–8.
  13. [13] Petrides AS: Liver disease and diabetes mellitus. Diabetes Revs 2:2–18,1994
  14. [14] Holstein A, Hinze S, Thieben E, Plaschke A, Egberts E-H: Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol17:677–681, 2002
  15. [15] Wiholm BE,Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993; 44:589-91.
  16. [16] Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Arch Intern Med 1992;152:2333-6.
  17. [17] Gowardman JR, Havill J. Fatal metformin induced lactic acidosis: case report. NZ Med J 1995; 108:230-1.
  18. [18] Bartley PC. Caution in use of metformin. Fellowship Affairs (Royal Australasian College of Physicians) 1996;(Nov):
  19. [19] Lee A, editor. Adverse Drug Reactions. 2nd ed. Great Britain: Pharmaceutical Press; 2009.
  20. [20] Sansom LN, editor. Australian pharmaceutical formulary and handbook. 21st ed. Canberra: Pharmaceutical Society of Australia; 2009.
  21. [21] Argov Z. Drug-induced myopathies. Curr Opin Neurol. 2000 Oct;13(5):541-5.
  22. [22] Bannwarth B. Drug-induced myopathies. Expert Opinion on Drug Safety. 2002;1(1):65-70.
  23. [23] Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factorsassociated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2): 153-62.
  24. [24] Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle & Nerve. 2003;27(2):142-56.
  25. [25] Saleh FG, Seidman RJ. Drug-induced myopathy and neuropathy. J Clin Neuromuscul Dis.2003 Dec;5(2):81-92.
  26. [26] Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. Oct 1976;61(4):485-92. [Medline].
  27. [27] Yamaguchi M, Niimi A, Minakuchi M, et al. Corticosteroid-induced myopathy mimicking therapy-resistant asthma. Ann Allergy Asthma Immunol. Oct 2007;99(4):371-4. [Medline].
  28. [28] Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. Jan 1993;16(1):84-90. [Medline].
  29. [29] Inder WJ, Jang C, Obeyesekere VR, et al. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clin Endocrinol (Oxf). Aug 4 2009;[Medline].
  30. [30] Betters JL, Long JH, Howe KS, et al. Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells. Muscle Nerve. Feb 2008;37(2):203-9. [Medline].
  31. [31] Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. Dec 2003;51(4):554-6. [Medline]. [Full Text].
  32. [32] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1): 91–99.
  33. [33] New England Healthcare Institute. Thinking outside the pillbox – A system-wide approach to improving patient medication adherence for chronic disease. Aug 2009. Available from: November 8, 2012.
  34. [34] Hughes D. When drugs don’t work – Economic assessment of enhanc¬ing compliance with interventions supported by electronic monitoring devices. Pharmacoeconomics. 2007;25(8):621–635.
  35. [35] Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medi¬cation compliance and persistence in pharmaco economic evaluations. Value Health. 2007;10(6):498–509.